Hipre5 mg

Hipre 5 mg is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of Hypertension and Coronary Artery Disease (such as Chronic Stable Angina, Vasospastic Angina and Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction < 40%) .

Calcium-channel blockers

Hipre 5 mg is a long-acting calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Thus it causes reduction in peripheral vascular resistance and contractile process in cardiac muscle and reduces blood pressure.The mechanism of the antihypertensive action is due to a direct relaxant effect on vascular smooth muscle. The precise mechanism by which Hipre 5 mg relieves angina has not been fully determined but Hipre 5 mg reduces total ischemic burden by the following two actions: Hipre 5 mg dilates peripheral arterioles and thus, reduces the total peripheral resistance (after load) against which the heart works. Since the heart rate remains stable, this unloading of the heart reduces myocardial energy consumption and oxygen requirements. The mechanism of action of Hipre 5 mg also probably involves dilatation of the main coronary arteries and coronary arterioles, both in normal and ischemic regions. This dilation increases myocardial oxygen delivery in patients with coronary artery spasm (prinzmetals or variant angina).

Adult: Starting dose 5 mg once daily with maximum dose 10 mg once daily.Pediatric: Starting dose 2.5 mg to 5 mg once daily.Small, Fragile and Elderly patients or patients with hepatic insufficiency: Starting dose 2.5 mg once daily.

Hipre 5 mg has been safely administered with thiazide diuretics, alpha blockers, beta blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerine, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. Hipre 5 mg has no effect on protein binding of digoxin, phenytoin, warfarin, or indomethacin. Administration of Hipre 5 mg with grapefruit or grapefruit juice is not recommended as bioavailability may be increased in some patients resulting in increased blood pressure lowering effects.

It is contraindicated in patients with known sensitivity to Hipre 5 mg.

Most common side effects are headache and edema which occurred in a dose related manner. Other side effects not dose related but reported with an incidence >1.0% are headache, fatigue, nausea, abdominal pain and somnolence.

Pregnancy Category C. There are no adequate and well-controlled studies of Hipre 5 mg in pregnant women. Hipre 5 mg should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether Hipre 5 mg is excreted in human milk. In the absence of this information, it is recommended that nursing be discontinued while Hipre 5 mg is administered.

Symptomatic hypotension is possible, particularly in patients with severe aortic stenosis. However, because of the gradual onset of action, acute hypotension is unlikely. Worsening angina and acute myocardial infarction can develop after starting or increasing the dose of Hipre 5 mg, particularly in patients with severe obstructive coronary artery disease. Titrate slowly when administering calcium channel blockers to patients with severe hepatic impairment.

In humans, experience with intentional overdose is limited.Symptoms: Available data suggest that large overdosage could result in excessive peripheral vasodilatation and possibly reflex tachycardia. Marked and probably prolonged systemic hypotension up to and including shock with fatal outcome have been reported.Management: Clinically significant hypotension due to Hipre 5 mg overdosage calls for active cardiovascular support including frequent monitoring of cardiac and respiratory function, elevation of extremities, and attention to circulating fluid volume and urine output. A vasoconstrictor may be helpful in restoring vascular tone and blood pressure, provided that there is no contraindication to its use. Intravenous calcium gluconate may be beneficial in reversing the effects of calcium channel blockade. Gastric lavage may be worthwhile in some cases. In healthy volunteers the use of charcoal up to 2 hours after administration of Hipre 5 mg 10 mg has been shown to reduce the absorption rate of Hipre 5 mg. Since Hipre 5 mg is highly protein-bound, dialysis is not likely to be of benefit.

keep in a dry place away from light and heat. Keep out of the reach of children.

Children with hypertension from 6 years to 17 years of age: 2.5 mg once daily as a starting dose, up-titrated to 5 mg once daily if blood pressure goal is not achieved after 4 weeks. Doses in excess of 5 mg daily have not been studied in pediatric patients.Children under 6 years old:  The effect of Hipre 5 mg on blood pressure in patients less than 6 years of age is not known.Elderly: Hipre 5 mg used at similar doses in elderly or younger patients is equally well tolerated. Normal dosage regimens are recommended in the elderly, but increase of the dosage should take place with care.Renal impairment: Changes in Hipre 5 mg plasma concentrations are not correlated with degree of renal impairment, therefore the normal dosage is recommended. Hipre 5 mg is not dialysable.Hepatic impairment: Dosage recommendations have not been established in patients with mild to moderate hepatic impairment; therefore dose selection should be cautions and should start at the lower end of the dosing range. The pharmacokinetics of Hipre 5 mg have not been studied in severe hepatic impairment. Hipre 5 mg should be initiated at the lowest dose (2.5 mg once daily) and titrated slowly in patients with severe hepatic impairment.